Established in 2007, Suzhou Ribo Life Science Co., Ltd. (Ribo) is a clinical stage company devoted to the development of innovative RNAi technologies and oligonucleotide therapeutics as an effort to address unmet clinical needs in the world with the tools, capacity and RNA therapeutics that we build up in China. Fueled by our mission to make China's oligonucleotide therapeutics serve the world, we seek.
Based on its cutting edge RNAi technologies, Ribo has established oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full life cycle of oligonucleotide therapeutics from early R&D to commercialization.
Ribo has applied for 230 domestic and foreign patents for innovative small RNAi technologies, of which 42 have been authorized by Aug. 2022. The research and development team of the company is consisted of many highly qualified Chinese experts and Chinese professional returnees with more than 20 years of expertise in the fields of RNAi biotechnology, nucleic acid chemistry, oligonucleotide therapeutic delivery, and drug development. So far, Ribo has established strategic partnership with a number of world leading nucleic acid-based technology and therapeutics companies, to facilitate the advancement of oligonucleotide therapeutics in China.
